BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154 PFaigtiuenrets 2with HR positive metastatic bone disease Patients with HR positive metastatic bone disease. (A) TTP_BD (P = 0.117), (B) OS (P = 0.104). Table 3: Characteristics of patients with HR positive and HR negative tumor Factors Age (yr, median, range) PS*** (ECOG ≥ 2) Pre-menopausal Post-menopausal HER2 positive DFI† (months, median, range) Initial stage IV Adjuvant treatment Radiotherapy Chemotherapy Hormonal therapy Metastatic sites Visceral (liver, lung) LNs‡ Soft tissue Bone only Weight bearing bone involvement Sum of metastatic sites (range) Cycles of palliative chemotherapy 1 2 ≥ 3 Palliative AI§ use Palliative anti-HER2 therapy Disease progression in bone SREs (except the first event) HR* positive tumor HR negative tumor BP group N = 202 46 (28–77) 9/138 (6.5%) 66/144(45.8%) 78/144(54.2%) 44 (21.8%) 27.5 (0–230) 44 (21.8%) 82 (40.6%) 139 (68.8%) 114 (56.4%) 80 (39.6%) 87 (43.1%) 57 (28.2%) 73 (36.1%) 174 (86.6%) 2 (1–6) 27 (13.4%) 43 (21.3%) 116 (57.4%) 159 (78.7%) 35/44 (79.5%) 96 (47.5%) 59 (29.2%) Non-BP group N = 28 50.5 (33–68) 0/16 (0%) 4/18 (22.2%) 14/18 (77.8%) 12 (42.9%) 26 (82.1%) 4 (14.3%) 15 (53.6%) 21 (75%) 17 (60.7%) 18 (64.3%) 12 (42.9%) 8 (28.6%) 6 (21.4%) 13 (46.4%) 3 (1–5) 4 (14.3%) 3 (10.7%) 17 (60.7%) 21 (75%) 10/12 (83.3%) 10 (35.7%) 4 (14.3%) P-value|| NS** NS 0.057 0.015 NS NS NS NS NS 0.013 NS NS NS < 0.001 NS NS NS NS NS NS BP group N = 60 43.5 (25–69) 1/28 (3.6%) 13/32 (40.6%) 19/32 (59.4%) 28 (46.7%) 18.5 (0–86) 17 (28.8%) 29 (48.3%) 37 (61.7%) 13 (21.7%) 36 (60%) 32 (53.3%) 21 (35%) 8 (13.3%) 51 (85%) 3 (1–5) 9 (15%) 10 (16.7%) 41 (68.3%) 9 (15%) 23/28 (82.1%) 23 (38.3%) 15 (25%) Non-BP group N = 27 P-value|| 50 (30–67) 2/11 (18.2%) 3/12 (25%) 9/12 (75%) 11 (40.7%) 18 (0–174) 7 (25.9%) 12 (44.4%) 17 (63%) 4 (14.8%) 19 (70.4%) 18 (66.7%) 12 (44.4%) 2 (7.4%) 12 (44.4%) 3 (1–6) 4 (14.8%) 10 (37%) 12 (44.4%) 2 (7.4%) 10/11 (90.9%) 6 (22.2%) 4 (14.8%) NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS < 0.001 NS NS Abbreviations: *, hormone receptor; **, not significant; ***, performance status; †, disease free interval; ‡, lymph nodes; § aromatase inhibitor; ||, P-value was obtained via chi-square test except variables of age and DFI which were obtained through Mann-Whitney U test. Page 5 of 9 (page number not for citation purposes)